Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxifloxacin-Based, Isoniazid-Sparing Regimen for Tuberculosis (TBTC/UITB Study 28)
2005-003312-29Phase 2Active
- Sponsor
- Unidad de Investigación en Tuberculosis de Barcelona
- Start
- Feb 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of moxifloxacin in pulmonary tuberculosis (TB) (2 arms), sponsored by Unidad de Investigación en Tuberculosis de Barcelona. Primary endpoint: Two-month sputum culture conversion. Started Feb 2006; status: active.
02
Drugs
moxifloxacin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on 2005-003312-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003312-29.